A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes

Stadler, M; Germing, U; Kliche, KO; Josten, KM; Kuse, R; Hofmann, WK; Schrezenmeier, H; Novotny, J; Anders, O; Eimermacher, H; Verbeek, W; Kreipe, HH; Heimpel, Hermann; Aul, C; Ganser, A

Erstveröffentlichung

2004

Metadata only
Search for full text

Wissenschaftlicher Artikel

Autoren

Stadler, M

Germing, U

Kliche, KO

Josten, KM

Kuse, R

et al.

Institutionen

UKU. Klinik für Innere Medizin III

Erschienen in

Leukemia ; 18 (2004), 3. - S. 460-465. - ISSN 0887-6924

Link zur Veröffentlichung

https://dx.doi.org/10.1038/sj.leu.2403239

Schlagwörter

myelodysplastic syndromes; immune modulation; antithymocyte globulin; antilymphocyte globulin; aplastic-anemia; bone-marrow; immunosuppressive therapy; classification; cyclosporine; prognosis; cells; atg

DDC-Sachgruppe

DDC 610 / Medicine & health

Metadata

Zur Langanzeige